Abstract
The research leading to these results has mainly received funding from the European Union Seventh Framework Programme [FP7/2007–2013] under Grant Agreement no 306242-NGS-PTL. In addition, this work was supported by grants from the Spanish Fondo de Investigaciones Sanitarias PI15/01471, PI18/01500, Instituto de Salud Carlos III (ISCIII), European Regional Development Fund (ERDF) “Una manera de hacer Europa”, “Consejeria de Educacion, Junta de Castilla y Leon” (SA085U16), “Proyectos de Investigacion del SACYL”, Spain: GRS 994/A/14, BIO/SA10/14, BIO/SA31/13, GRS 1172/A/15,“Fundacion Memoria Don Samuel Solorzano Barruso”, by grants (RD12/0036/0069) from Red Tematica de Investigacion Cooperativa en Cancer (RTICC), Centro de Investigacion Biomedica en Red de Cancer (CIBERONC) CB16/12/00233 and USAL Programa XIII. M. Hernandez-Sanchez is supported by FEHH-Janssen (“Sociedad Espanola de Hematologia y Hemoterapia”). M Quijada-Alamo is supported by an “Ayuda Predoctoral de la Junta de Castilla y Leon” (JCYL-EDU/529/2017). We are grateful to I. Rodriguez, S. Gonzalez, T.Prieto, M. A. Ramos, A. Martin, A. Diaz, A. Simon, M.del Pozo, V. Gutierrez and S. Pujante from Centro de Investigacion del Cancer, Salamanca, for their technical assistance. D. Tamborero is supported by project SAF2015–74072-JUN, which is funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Dearrollo Regional (FEDER). This work was supported by Seventh Framework Programme (NGS-PTL/2012–2015/no.306242) and Ministry of Education, Youth and Sports (2013–2015, no. 7E13008); by the Ministry of Education, Youth and Sports of the Czech Republic under the CEITEC 2020 project (LQ1601); by the Ministry of Health, Czech Republic - conceptual development of research organization (FNBr, 65269705); by the Specific University Research (nr. MUNI/A/0968/2017) provided by MEYS; and by the project CZ.02.1.01/0.0/0.0/16_013/0001634 National Center for Medical Genomic - modernization of infrastructure and research of genetic variation in the population, funded by OP RDE. We acknowledge the CF Genomics CEITEC MU supported by the NCMG research infrastructure (LM2015091 funded by MEYS CR) for their support with obtaining the scientific data presented in this paper. We acknowledge S. Takacova from CEITEC MU for her help with the sample selection and processing.
Highlights
Immunoglobulin light chain amyloidosis (AL) results from extracellular deposition of light chain-composed amyloid fibrils leading to organ dysfunction
High and very high international prognostic scoring system (IPSS-R) (International prognostic scoring system-revised) and male sex were found to be significantly associated with a high red cell transfusion intensity (TI) (IRR 2.0, 95% confidence interval (CI) 1.9–2.1; incidence rate ratios (IRRs) 2.7, 95% confidence intervals (CI) 2.6–3.0; and IRR 2.0, 95% CI 1.6–1.8, respectively) (Table 1; Fig. S2A)
−CD45RA−CD90−), multilymphoid progenitor (MLP; CD34+CD38−CD45RA+CD90−), as well as primitive (CD34+CD38−) and committed CD34+CD38+ progenitor cells (Fig. 2d), indicating that mesenchymal NF-κB signaling attenuates hematopoietic stem/progenitor cells (HSPCs) number and function, at least partially, independent of its effect on mesenchymal cell proliferation. In this brief communication, we demonstrate that mesenchymal NF-κB activation is a common finding in LR-myelodysplastic syndromes (MDS) patients leading to transcriptional upregulation of inflammatory programs associated with negative regulation of hematopoiesis and attenuation of HSPC numbers and function
Summary
The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. To view a copy of this license, visit http://creativecommons. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
